<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460276</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated Adults.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1109</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101109</ELocationID><Abstract><AbstractText>The SARS-CoV-2 evolution trajectory remains uncertain, and the antigenic characteristics of future variants are highly unpredictable. We report the immunogenicity and safety of multivalent COVID-19 vaccines, SCTV01E and SCTV01E-1, against Omicron BA.5. This phase 2 trial randomized 400 adults into two cohorts, 160 unvaccinated (3 doses) and 240 previously vaccinated (2 doses) individuals to receive 30 µg SCTV01E-1 or 30 µg SCTV01E (1:1) between 4 November and 28 November 2022. Among the unvaccinated cohort, day 42 geometric mean fold rises (GMFRs) of neutralizing antibodies (nAb) against Omicron BA.5 were reported to be 12.8× and 20.5× over day 0 for SCTV01E-1 and SCTV01E, respectively. On day 178, both vaccines increased geometric mean titers (GMTs) of nAb against BA.5 following the booster dose compared to pre-booster levels on D150. Similar frequencies of solicited [6.2% (5/81) and 7.6% (6/79)] and unsolicited [11.1% (9/81) and 10.1% (8/79)] adverse events (AEs) were reported in SCTV01E-1 and SCTV01E groups, respectively. Grade 3 or more AEs were &lt; 2% in both vaccine groups [SCTV01E-1: 1.2% (1/81), SCTV01E: 1.3% (1/79)]. In the previously vaccinated cohort, similar GMFRs were reported on day 28 (SCTV01E-1: 9.4× and SCTV01E: 8.7×) over baseline (D0). On day 148, both vaccines showed increased nAb levels with similar GMFRs over D120. Comparable incidences of solicited [13.2% (16/121) and 10.9% (13/119)] and unsolicited [17.4% (21/121) and 10.9% (13/119)] AEs were reported in SCTV01E-1 and SCTV01E groups, respectively. Numerically identical ≥ grade 3 AEs [SCTV01E-1: 1.7% (2/121) and SCTV01E: 1.7% (2/119)] were reported. This trial demonstrates the effectiveness of updated multivalent vaccines with acceptable safety profiles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hannawi</LastName><ForeName>Suad</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5689-6710</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai 00000, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abuquta</LastName><ForeName>Alaa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1621-0777</Identifier><AffiliationInfo><Affiliation>Accident and Emergency Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai 00000, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eldin</LastName><ForeName>Linda Saf</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>General Surgery Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai 00000, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Aala</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6875-5069</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Al Kuwait-Dubai (ALBaraha) Hospital, Dubai 00000, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alamadi</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ear, Nose and Throat Department (ENT), Al Kuwait-Dubai (ALBaraha) Hospital, Dubai 00000, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Cuige</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baidoo</LastName><ForeName>Adam Abdul Hakeem</ForeName><Initials>AAH</Initials><AffiliationInfo><Affiliation>Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xinjie</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Huo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinxiu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Liangzhi</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4504-7622</Identifier><AffiliationInfo><Affiliation>Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Culture Engineering Center, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z231100004823003</GrantID><Agency>Beijing Science and Technology Planning Project</Agency><Country /></Grant><Grant><GrantID>2023YFC3042100</GrantID><Agency>National Key Research and Development Program of China</Agency><Country /></Grant><Grant><GrantID>2022YFC0870600</GrantID><Agency>National Key Research and Development Program of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">multivalent vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>Sinocelltech Ltd. sponsored this work. Liangzhi Xie has potential stock option interests in the company. Cuige Gao, Huo Su, Jinxiu Zhang, Xinjie Yang, and Adam Abdul Hakeem Baidoo are employees of Sinocelltech Ltd. All authors declare no other conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460276</ArticleId><ArticleId IdType="pmc">PMC11510771</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101109</ArticleId><ArticleId IdType="pii">vaccines12101109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H., Moir M., Everatt J., Giovanetti M., Scheepers C., Wilkinson E., Subramoney K., Makatini Z., Moyo S., Amoako D.G., et al. Emergence of SARS-CoV-2 omicron lineages BA. 4 and BA. 5 in South Africa. Nat. Med. 2022;28:1785–1790. doi: 10.1038/s41591-022-01911-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01911-2</ArticleId><ArticleId IdType="pmc">PMC9499863</ArticleId><ArticleId IdType="pubmed">35760080</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana R., Moyo S., Amoako D.G., Tegally H., Scheepers C., Althaus C.L., Anyaneji U.J., Bester P.A., Boni M.F., Chand M., et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603:679–686. doi: 10.1038/s41586-022-04411-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04411-y</ArticleId><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A.S., Gribben C., Bishop J., Hanlon P., Caldwell D., Wood R., Reid M., McMenamin J., Goldberg D., Stockton D., et al. Effect of vaccination on transmission of SARS-CoV-2. N. Engl. J. Med. 2021;385:1718–1720. doi: 10.1056/NEJMc2106757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2106757</ArticleId><ArticleId IdType="pmc">PMC8451182</ArticleId><ArticleId IdType="pubmed">34496200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai J., Wang X., He X., Zhao X., Zhang Y., Jiang Y., Li M., Cui Y., Chen Y., Qiao R., et al. Antibody evasion of SARS-CoV-2 Omicron BA. 1, BA. 1.1, BA. 2, and BA. 3 sub-lineages. Cell Host Microbe. 2022;30:1077–1083.e4. doi: 10.1016/j.chom.2022.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.05.001</ArticleId><ArticleId IdType="pmc">PMC9080084</ArticleId><ArticleId IdType="pubmed">35594867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Yisimayi A., Jian F., Song W., Xiao T., Wang L., Du S., Wang J., Li Q., Chen X., et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602. doi: 10.1038/s41586-022-04980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann N.P., Miller J., Collier A.R., Ventura J.D., Yu J., Rowe M., Bondzie E.A., Powers O., Surve N., Hall K., et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4, and BA. 5. N. Engl. J. Med. 2022;387:86–88. doi: 10.1056/NEJMc2206576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206576</ArticleId><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Director-General’s Opening Remarks at the Media Briefing—5 May 2023.  [(accessed on 5 May 2023)].  Available online:  https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing.</Citation></Reference><Reference><Citation>Vaccines and Related Biological Products Advisory Committee June 15, 2023 Meeting Announcement.  [(accessed on 15 June 2023)]; Available online:  https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-15-2023-meeting-announcement.</Citation></Reference><Reference><Citation>Weekly Epidemiological Update on COVID-19—9 November 2022.  [(accessed on 9 November 2022)].  Available online:  https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19.</Citation></Reference><Reference><Citation>Wang R., Huang H., Yu C., Sun C., Ma J., Kong D., Lin Y., Zhao D., Zhou S., Lu J., et al. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants. Sci. China Life Sci. 2022;66:1818–1830. doi: 10.1007/s11427-022-2207-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-022-2207-7</ArticleId><ArticleId IdType="pmc">PMC9811042</ArticleId><ArticleId IdType="pubmed">36598621</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannawi S., Saf Eldin L., Abuquta A., Alamadi A., Mahmoud S.A., Hassan A., Xu S., Li J., Liu D., Baidoo A.A., et al. Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men. Nat. Commun. 2023;14:4043. doi: 10.1038/s41467-023-39766-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39766-x</ArticleId><ArticleId IdType="pmc">PMC10329711</ArticleId><ArticleId IdType="pubmed">37422518</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannawi S., Yan L., Eldin L.S., Abuquta A., Alamadi A., Mahmoud S.A., Hassan A., Zhang M., Gao C., Chen Y., et al. Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: A randomized phase 3 trial. EClinicalMedicine. 2023;64:102195. doi: 10.1016/j.eclinm.2023.102195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102195</ArticleId><ArticleId IdType="pmc">PMC10507195</ArticleId><ArticleId IdType="pubmed">37731938</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Zhao K., Han J., Hu Z., Zhang T., Wang Y., Shi R., Li Y., Song Q., Du H., et al. Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial. J. Infect. 2023;86:154–225. doi: 10.1016/j.jinf.2022.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.11.008</ArticleId><ArticleId IdType="pmc">PMC9672836</ArticleId><ArticleId IdType="pubmed">36403700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeri I., Whelan M.G., Ware H., Subissi L., Nardone A., Lewis H.C., Li Z., Ma X., Valenciano M., Cheng B., et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med. 2022;19:e1004107. doi: 10.1371/journal.pmed.1004107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004107</ArticleId><ArticleId IdType="pmc">PMC9648705</ArticleId><ArticleId IdType="pubmed">36355774</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Iketani S., Guo Y., Chan J.F., Wang M., Liu L., Luo Y., Chu H., Huang Y., Nair M.S., et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602:676–681. doi: 10.1038/s41586-021-04388-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04388-0</ArticleId><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Link-Gelles R., Patel M.M. Long-term Protection Associated With COVID-19 Vaccination and Prior Infection. JAMA. 2022;328:1402–1404. doi: 10.1001/jama.2022.14660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.14660</ArticleId><ArticleId IdType="pmc">PMC11331586</ArticleId><ArticleId IdType="pubmed">36156638</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Zhang L., Liang Z., Wang N., Liu S., Li T., Yu Y., Cui Q., Wu X., Nie J., et al. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses. Signal Transduct. Target. Ther. 2022;7:256. doi: 10.1038/s41392-022-01123-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01123-7</ArticleId><ArticleId IdType="pmc">PMC9328627</ArticleId><ArticleId IdType="pubmed">35896529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyke K.E., Atmar R.L., Islas C.D., Posavad C.M., Szydlo D., Chourdhury R.P., Deming M.E., Eaton A., Jackson L.A., Branche A.R., et al. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep. Med. 2022;3:100679. doi: 10.1016/j.xcrm.2022.100679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100679</ArticleId><ArticleId IdType="pmc">PMC9212999</ArticleId><ArticleId IdType="pubmed">35798000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Bowen A., Tam A.R., Valdez R., Stoneman E., Mellis I.A., Gordon A., Liu L., Ho D.D. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. Lancet Infect. Dis. 2023;23:527–528. doi: 10.1016/S1473-3099(23)00181-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00181-0</ArticleId><ArticleId IdType="pmc">PMC10058662</ArticleId><ArticleId IdType="pubmed">37003292</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava K., Carreño J.M., Gleason C., Monahan B., Singh G., Abbad A., Tcheou J., Raskin A., Kleiner G., van Bakel H. Kinetics and durability of humoral responses to SARS-CoV-2 infection and vaccination. medRxiv. 2023 doi: 10.1101/2023.08.26.23294679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.08.26.23294679</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheetham N.J., Kibble M., Wong A., Silverwood R.J., Knuppel A., Williams D.M., Hamilton O.K., Lee P.H., Bridger Staatz C., Di Gessa G. Antibody levels following vaccination against SARS-CoV-2: Associations with post-vaccination infection and risk factors in two UK longitudinal studies. Elife. 2023;12:e80428. doi: 10.7554/eLife.80428.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.80428</ArticleId><ArticleId IdType="pmc">PMC9940912</ArticleId><ArticleId IdType="pubmed">36692910</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzese M., Coppola L., Silva R., Santini S.A., Cinquanta L., Ottomano C., Salvatore M., Incoronato M. SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged≤ 60 years: One year of surveillance. Front. Immunol. 2022;13:947187. doi: 10.3389/fimmu.2022.947187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.947187</ArticleId><ArticleId IdType="pmc">PMC9566572</ArticleId><ArticleId IdType="pubmed">36248864</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Smatti M.K., Coyle P., Al-Kanaani Z., et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 2022;387:21–34. doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Rifai R.H., Acuna J., Al Hossany F.I., Aden B., Al Memari S.A., Al Mazrouei S.K., Ahmed L.A. Epidemiological characterization of symptomatic and asymptomatic COVID-19 cases and positivity in subsequent RT-PCR tests in the United Arab Emirates. PLoS ONE. 2021;16:e0246903. doi: 10.1371/journal.pone.0246903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246903</ArticleId><ArticleId IdType="pmc">PMC7880695</ArticleId><ArticleId IdType="pubmed">33577582</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R., Gui X., Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. JAMA Netw. Open. 2020;3:e2010182. doi: 10.1001/jamanetworkopen.2020.10182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.10182</ArticleId><ArticleId IdType="pmc">PMC7254178</ArticleId><ArticleId IdType="pubmed">32459353</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier A.-R.Y., Yu J., McMahan K., Liu J., Chandrashekar A., Maron J.S., Atyeo C., Martinez D.R., Ansel J.L., Aguayo R., et al. Differential kinetics of immune responses elicited by COVID-19 vaccines. N. Engl. J. Med. 2021;385:2010–2012. doi: 10.1056/NEJMc2115596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2115596</ArticleId><ArticleId IdType="pmc">PMC8531985</ArticleId><ArticleId IdType="pubmed">34648703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Jiang S., Ma W., Li X., Wei K., Xie F., Zhao C., Zhao X., Li C., Qiao R., et al. Enhanced neutralization of SARS-CoV-2 XBB sub-lineages and BA. 2.86 by a tetravalent COVID-19 vaccine booster. bioRxiv. 2023 doi: 10.1101/2023.09.14.557682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.09.14.557682</ArticleId><ArticleId IdType="pubmed">38029742</ArticleId></ArticleIdList></Reference><Reference><Citation>Formeister E.J., Wu M.J., Chari D.A., Meek R., Rauch S.D., Remenschneider A.K., Quesnel A.M., de Venecia R., Lee D.J., Chien W., et al. Assessment of sudden sensorineural hearing loss after COVID-19 vaccination. Arch. Otolaryngol. Neck Surg. 2022;148:307–315. doi: 10.1001/jamaoto.2021.4414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2021.4414</ArticleId><ArticleId IdType="pmc">PMC8874871</ArticleId><ArticleId IdType="pubmed">35201274</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>